The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of six cycles of epirubicin and paclitaxel (ET) versus four cycles of epirubicin and cyclophosphamide, followed by four cycles of paclitaxel (EC-T) as adjuvant therapy for operable breast cancer in women with positive axillary nodes.
Peng Yuan
No relevant relationships to disclose
Jiayu Wang
No relevant relationships to disclose
Fei Ma
No relevant relationships to disclose
Ying Fan
No relevant relationships to disclose
Yang Luo
No relevant relationships to disclose
Ruigang Cai
No relevant relationships to disclose
Pin Zhang
No relevant relationships to disclose
Qing Li
No relevant relationships to disclose
Binghe Xu
No relevant relationships to disclose